Planta Med 2025; 91(15): 880-890
DOI: 10.1055/a-2686-6315
Reviews

Factors Influencing Clinical Trials of Herbal Medicinal Products – Using Ginger as Example

Authors

  • Ingrid Hook

    1   School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin, Dublin, Ireland
    2   ESCOP, Notaries House, Exeter, UK
  • Liselotte Krenn

    2   ESCOP, Notaries House, Exeter, UK
    3   Division of Pharmacognosy, University Vienna, Austria
  • Barbara Steinhoff

    2   ESCOP, Notaries House, Exeter, UK
  • Evelyn Wolfram

    2   ESCOP, Notaries House, Exeter, UK
    4   Natural Products and Phytopharmacy Research Group, Institute of Chemistry & Biotechnology, Zürich University of Applied Sciences, Wädenswil, Switzerland

Abstract

Ginger (Zingiber officinale) has a global use as a spice, an ingredient of beverages, food supplements (syn. dietary supplements), as well as herbal medicinal products. Since the last update of ginger in ESCOP Monographs in 2009 a significant number of papers concerning its bioactive constituents and clinical uses have been published. From this large number and selecting those references (almost 500) considered most relevant to clinical aspects and therapeutic indications, the following issues are considered to be potentially important to research on other medicinal plants: [i] quality assessment; [ii] pre-clinical (in vivo) studies; [iii] quality of clinical trials; [iv] ethnicity of clinical trial participants and [v] effects of sex-gender on activity and therapeutic indications.



Publication History

Received: 27 March 2025

Accepted after revision: 04 August 2025

Article published online:
08 September 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany